Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Pursuant to the Jan 2013 Settlement Agreement is PTSC getting 50%

If so, then 50% of what????

TPL Opening Disclosure Statement 12-23-13 found in BaNosser post as follows:

http://agoracom.com/ir/patriot/forums/discussion/topics/596380-tpl-bk-documents-dec-16-17-23/messages/1870873#message

-->

p.78 Currently, revenues from MMP are paid to the contingency firm handling litigation, Agility. The payment to Agility varies significantly depending on whether the licensee is a defendant or not. PDS is also obligated to pay all vendors from MMP revenue, including Alliacense for sales, marketing, litigation support and prosecution and maintenance, and all vendors used in relation to litigation preparation including expert witnesses, document production vendors, etc. PDS also pays MMP inventor Charles Moore a monthly consulting fee and advances payments to Patriot and Mr. Moore for their percentage share of returns pursuant to the January 2013 Settlement Agreement . Finally, the remainder is split amongst TPL, Patriot and Moore. While TPL’s share of MMP revenueis approximately 26%, that number drops below 10% historically after taking into account all PDS payables.

Share
New Message
Please login to post a reply